Zenas BioPharma (NASDAQ:ZBIO) Price Target Raised to $44.00

Zenas BioPharma (NASDAQ:ZBIO) had its target price upped by HC Wainwright from $30.00 to $44.00 in a research report sent to investors on Tuesday, MarketBeat Ratings reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Zenas BioPharma’s Q3 2025 earnings at ($1.12) EPS, Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($3.47) EPS, FY2026 earnings at ($3.44) EPS, FY2027 earnings at ($2.82) EPS, FY2028 earnings at ($3.13) EPS and FY2029 earnings at ($2.30) EPS.

ZBIO has been the topic of a number of other reports. Jefferies Financial Group reissued a “buy” rating and issued a $52.00 price objective on shares of Zenas BioPharma in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Wednesday, October 8th. Wedbush restated an “outperform” rating and issued a $45.00 price target (up from $40.00) on shares of Zenas BioPharma in a research note on Monday. Morgan Stanley lifted their price target on Zenas BioPharma from $31.00 to $34.00 and gave the stock an “overweight” rating in a report on Monday. Finally, Wall Street Zen downgraded Zenas BioPharma from a “hold” rating to a “sell” rating in a report on Friday, September 26th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $44.33.

Zenas BioPharma Price Performance

ZBIO stock opened at $29.88 on Tuesday. The business’s 50-day moving average is $21.81 and its two-hundred day moving average is $15.24. The firm has a market capitalization of $1.26 billion and a P/E ratio of -5.13. Zenas BioPharma has a 1 year low of $5.83 and a 1 year high of $34.33.

Zenas BioPharma (NASDAQ:ZBIO) last released its earnings results on Tuesday, August 12th. The company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.23).

Insider Buying and Selling

In other news, Director Hongbo Lu bought 263,160 shares of the firm’s stock in a transaction that occurred on Tuesday, October 7th. The stock was purchased at an average cost of $19.00 per share, with a total value of $5,000,040.00. Following the transaction, the director directly owned 321,983 shares in the company, valued at $6,117,677. This trade represents a 447.38% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Jason Raleigh Nunn purchased 63,158 shares of the company’s stock in a transaction that occurred on Thursday, October 9th. The shares were purchased at an average price of $19.00 per share, for a total transaction of $1,200,002.00. Following the purchase, the director directly owned 1,173,395 shares in the company, valued at $22,294,505. The trade was a 5.69% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 923,035 shares of company stock valued at $17,628,163 over the last ninety days. Company insiders own 16.50% of the company’s stock.

Institutional Investors Weigh In On Zenas BioPharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Federated Hermes Inc. boosted its holdings in shares of Zenas BioPharma by 60.8% in the second quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock valued at $18,041,000 after acquiring an additional 703,838 shares during the period. Geode Capital Management LLC raised its position in Zenas BioPharma by 4.6% in the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after purchasing an additional 16,461 shares during the last quarter. Jefferies Financial Group Inc. purchased a new stake in Zenas BioPharma in the 1st quarter valued at $348,000. Nuveen LLC acquired a new stake in Zenas BioPharma during the 1st quarter worth $250,000. Finally, Rhumbline Advisers boosted its stake in Zenas BioPharma by 71.3% during the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock worth $191,000 after purchasing an additional 8,207 shares during the period.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.